Over 7,500 investors have already joined Cytonics, a biotech startup developing what could be the first cure for osteoarthritis (OA). And they aim to win one of medicine’s biggest unsolved opportunities.
Over $560 billion is spent managing OA every year. For 500+ million patients worldwide*, the options have always been the same: manage the pain, slow the damage, repeat.
Cytonics may be about to change that.
Here's why this emerging biotech is turning heads, and why early-stage investors are paying attention:
-
Proven technology. Their first-generation therapy has already treated 10,000+ patients.
-
A scalable path forward. Cytonics is now developing a mass-producible version aimed at FDA approval.
-
A true disease-modifier. If approved, Cytonics' therapy would be the first to halt cartilage destruction and promote regrowth, rather than just dull the pain.
And this mass-producible, 200% more potent version of their first-gen therapy has just cleared Phase 1 safety trials. Now, the company is moving into the next phase of development.
If successful, this is historically when Big Pharma acquires biotech targets: when efficacy data exists but no price has been set.
Merck acquired Prometheus for $10.8 billion. GSK acquired Bellus for $2 billion**. While nothing's guaranteed, an uncured $560 billion disease is exactly what Big Pharma looks for.
Potential medical breakthroughs like this are rare. The chance to invest in an early clinical stage is even rarer.
Time’s almost up to become an early-stage shareholder. Join 7,500+ people and invest in Cytonics before the round closes.
